A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
Key facts
- Where
- Alexandria, Buffalo, Chico, Coon Rapids, Cranberry Township, Dallas, El Paso, Medford, and Petaluma, United StatesSee the 9 sites
Where in United States
- Vance Thompson VisionAlexandria, United StatesNo longer taking part
- Ross Eye InstituteBuffalo, United StatesNo longer taking part
- North Valley Eye CareChico, United StatesNo longer taking part
- Twin Cities Eye ConsultantsCoon Rapids, United StatesNo longer taking part
- Scott & Christie Eyecare AssociatesCranberry Township, United StatesNo longer taking part
- Key-Whitman Eye CenterDallas, United StatesNo longer taking part
- El Paso Eye SurgeonsEl Paso, United StatesNo longer taking part
- Cataract & Laser InstituteMedford, United StatesNo longer taking part
- North Bay Eye AssociatesPetaluma, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Iantrek, Inc.
- Trial code
- NCT07520175
- Record updated
- 13 October 2026
- Original description
The goal of this study is to learn about outcomes after bio-reinforced canaloplasty surgery in patients with OAG. The key question the study aims to answer is:Read full original descriptionShow less
An Observational Study of Safety and Effectiveness Outcomes Following Bio-Reinforced Canaloplasty for Trabecular Outflow Enhancement in Eyes With Open-Angle Glaucoma (The BOOST Study)
The goal of this study is to learn about outcomes after bio-reinforced canaloplasty surgery in patients with OAG. The key question the study aims to answer is:
How much does the surgical procedure lower pressure inside the eye and what is the durability of this effect?
Participants will return for periodic eye exams for 2 years following surgery.
Inclusion: Diagnosis of OAG in the study eye and a candidate for bio-reinforced canaloplasty for aqueous outflow enhancement, as determined by investigator.
Exclusion: Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic, or neovascular glaucoma in the study eye 2. Previous minimally invasive or filtering glaucoma surgery in the study eye 3. Previous IOP-lowering procedure ≤ 12 weeks prior to bio-reinforced canaloplasty in the study eye 5. Previous investigational, or non-standard of care procedures and/or treatments ≤ 12 weeks prior to bio-reinforced canaloplasty; -.